Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis/BMS deal closes

This article was originally published in The Tan Sheet

Executive Summary

Swiss firm completes $385 mil. strategic acquisition of Mead Johnson's global adult nutritionals business from Bristol-Meyers Squibb Feb. 13. Novartis said the all-cash deal did not require any divestments for regulatory approval. The firms announced the deal in December (1"The Tan Sheet" Dec. 22, 2003, p. 12)...

You may also be interested in...

Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis

The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise

Amwell Stock Rises 28% In Market Debut

Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.

Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents

Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts